Patent Opposition Database

Hide annotations

Related patent application (please put in national patent application/publication number or PCT application/publication number): AR087177A1
Who filed: CILFA
Country: Argentina
Opposition type: Pre-Grant
Opposition status: Under Examination
Date: 11-09-2015
Patent type: Formulations

Click within the document, or manually enter the page number below

CILFA opposition, agomelatine, (AR095152A1)

Countries: Argentina Date: 2015
CILFA opposition, lactoferrin, (AR093894A1)

Countries: Argentina Date: 2015
CILFA opposition, metformin, simvastatin or atorvastatin,benazepril, lisinopril or losartan, aspirin, (AR091739A1)

Countries: Argentina Date: 2015
CILFA opposition, 1 1 -beta-hydroxysteroid dehydrogenase 1 , (AR090999A1)

Countries: Argentina Date: 2015
CILFA opposition, ranibizumab and bevacizumab, (AR092372A1)

Countries: Argentina Date: 2015
CILFA opposition, tobramycin, (AR092318A1)

Countries: Argentina Date: 2015
CILFA opposition, levothyroxine, (AR092151A1)

Countries: Argentina Date: 2015
Fundación Grupo Efecto Positivo opposition, Sofosbuvir, (WO/2008/121634)

Countries: Argentina Date: 2015
Fundación Grupo Efecto Positivo opposition, Tenofovir 300mg+ Emtricitabina 200mg (TDF+FTC), (n/a)

Countries: Argentina Date: 2015
CILFA opposition, celecoxib, (P990106069)

Countries: Argentina Date: 2004

Cilfa Opposition, Montelukast And Levocetirizine, (Ar087177 A1)